 | Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
In 2007, Amgen Inc - the world’s largest biotechnology company - achieved total sales of $14.7m, despite a turbulent year marked by regulatory, pricing and reimbursement issues. Amgen has now firmly established itself as a Top-20 international pharmaceutical company. According to sales data for 2007, Amgen is also ranked as the 11th largest pharmaceutical company worldwide based on total sales value. This is a remarkable achievment for a biotechnology company founded in 1980. This independent and unique report will help you to understand why Amgen is so competitive and what roles it and similar companies will play in the global pharmaceutical market from the present onwards. Amgen is a vital company for competitive analysis and as an indicator of success factors required in the new competitive environment in healthcare. Our new report Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 will help you to understand those developments and their significance for the biotechnology and pharmaceutical industries, as well as related sectors. Amgen’s proprietary products comprise human therapeutic drugs: Epogen (epoetin alfa) Aranesp (darbepoetin alfa) Neupogen (filgrastim) Neulasta (pegfilgrastim) Kineret (anakinra) Enbrel (etanercept). Visiongain believes that the combined revenues for Amgen's key drugs will reach $20bn by 2012. Amgen’s leadership in the biotech sector over the years has been driven largely by well-thought out strategic activities. Those corporate developments comprise key mergers and acquisitions (M&As) and strategic alliances. Amgen, although presently going through restructuring in some of its departments, clearly has a robust corporate strategy that should serve it well for years to come, driving strong growth and further innovation. Moreover, Amgen has a noteworthy commercial R&D pipeline that should generate significant dividends in the long-term, visiongain believes. Our new Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 report examines that company critically, with in-depth analysis. Importantly, visiongain discusses Amgen in the context of the wider pharmaceutical market. This totally independent market-based research involved a detailed study of commercial documents, databases, company reports and relevant news. Importantly, visiongain applied techniques such as financial forecasting, study of market shares, SWOT analysis and qualitative projections. The result is a comprehensive market-based report with detailed analyses and informed opinion. Why you should buy this reportIn particular, Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023 concentrates on the following essential aspects of Amgen and the market in which it competes: Detailed analysis of Amgen’s present challenges, achievements and future prospects Corporate Sales forecast for Amgen Sales forecasts for leading drugs Discussions of issues affecting the relevant market segments Competitor analysis Drivers and opportunities for Amgen Restraints and threats facing the company Discussions of corporate strategy in the context of the market Strategic alliances and licensing Pipeline developments and their implications for the future International operations Litigation proceedings. Amgen, a leader in biotechnology, will generate high revenues and significant profitability in the years ahead, visiongain concludes. Sales of biotech drugs are increasing worldwide, with greater reliance on those agents as time goes by. Certainly, the future prospects for leading biotech companies are vast, especially with the dawn of more-personalised molecular medicine with greater efficacy and safety profiles. Also, there are increasing numbers of niche markets for biotech drugs, especially for serious, difficult-to-treat conditions. Moreover, visiongain believes that Amgen will restore investors’ confidence through its impressive R&D pipeline. Amgen will remain a prominent and highly innovative force in the global pharma industry – leader of the new breed of companies in this large, but increasingly turbulent, industry. By purchasing this report, you will be better prepared to appreciate those developments fully, benefiting from the opportunities available in the changing pharma market. Now is the time to act. If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.- PRICING - - Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD $5,995.00. This is not suitable for library usage. - Allow your whole company to have access to this information for only USD $9,995.00. Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD $13,995.00July 2008
Table of Contents
License
|
|
|
|
